Comparison of estramustine phosphate, methotrexate and cis-platinum in patients with advanced, hormone refractory prostate cancer

S. A. Loening, S. Beckley, M. F. Brady, T. M. Chu, J. B. deKernion, C. Dhabuwala, J. F. Gaeta, R. P. Gibbons, C. F. McKiel, D. G. McLeod, J. E. Pontes, G. R. Prout, P. T. Scardino, J. U. Schlegel, J. D. Schmidt, W. W. Scott, N. H. Slack, M. S. Soloway, G. P. Murphy

Research output: Contribution to journalArticle

65 Scopus citations

Abstract

In this clinical trial of men with advanced prostatic cancer no longer responsive to hormone therapy 189 were randomized to receive estramustine phosphate, methotrexate or cis-platinum. Response evaluations were done in 158 cases. Objective response rates (complete, partial or stabilization of disease) were 34 per cent for estramustine phosphate, 36 per cent for cis-platinum and 41 per cent for methotrexate. Subjective parameters indicated a substantial advantage for pain improvement with methotrexate or cis-platinum over estramustine phosphate. Probabilities of continued response indicated some advantage for methotrexate and median response durations at this time were twice as long for methotrexate (32 weeks) as for cis-platinum (16 weeks), with estramustine phosphate intermediate (23 weeks). Survival rates for the original treatment randomization groups were not different at this time. Side effects of estramustine phosphate consisted primarily of nausea and vomiting and/or anorexia but to a lesser extent than with cis-platinum. These effects were somewhat less for methotrexate, for which the major side effects were stomatitis and leukopenia, as well as hepatic toxicity reflected by elevated serum glutamic oxaloacetic transaminase levels. Other side effects of cis-platinum were less than for methotrexate (no stomatitis), except for signs of renal toxicity (elevations in blood urea nitrogen and serum creatinine), which were greater. Methotrexate had a relatively high level of activity against metastatic, progressive, hormone nonresponsive prostatic cancer, with side effects that were substantial but manageable.

Original languageEnglish (US)
Pages (from-to)1001-1006
Number of pages6
JournalUnknown Journal
Volume129
Issue number5
DOIs
StatePublished - Jan 1 1983

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Comparison of estramustine phosphate, methotrexate and cis-platinum in patients with advanced, hormone refractory prostate cancer'. Together they form a unique fingerprint.

  • Cite this

    Loening, S. A., Beckley, S., Brady, M. F., Chu, T. M., deKernion, J. B., Dhabuwala, C., Gaeta, J. F., Gibbons, R. P., McKiel, C. F., McLeod, D. G., Pontes, J. E., Prout, G. R., Scardino, P. T., Schlegel, J. U., Schmidt, J. D., Scott, W. W., Slack, N. H., Soloway, M. S., & Murphy, G. P. (1983). Comparison of estramustine phosphate, methotrexate and cis-platinum in patients with advanced, hormone refractory prostate cancer. Unknown Journal, 129(5), 1001-1006. https://doi.org/10.1016/S0022-5347(17)52509-4